Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder

In patients with attention deficit hyperactivity disorder (ADHD), norepinephrine reuptake inhibitors like atomoxetine may show mild effectiveness in addressing both inattention and hyperactivity/impulsivity. The relative efficacy of branded extended-release viloxazine (viloxazine ER) compared to generic atomoxetine remains unknown. This Adis Summary of Research summarizes the efficacy and tolerability of a voluntary switch from atomoxetine to viloxazine ER, prompted by adverse events or inadequate response, based on a retrospective chart review conducted in the USA. The switch improved ADHD symptoms and tolerability.

Authors and Affiliations

1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

   Yahiya Y. Syed

Corresponding author

Correspondence to Yahiya Y. Syed.

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions